AI Engines For more Details: Perplexityβ Kagi Labsβ Youβ
Gastroesophageal Reflux Disease (GERD): Proton pump inhibitors are frequently prescribed for the treatment of GERD, a chronic condition where stomach acid flows back into the esophagus, causing symptoms such as heartburn, regurgitation, and chest pain. PPIs help alleviate symptoms and promote healing of the esophageal lining.
Peptic Ulcers: PPIs are effective in treating peptic ulcers, which are open sores that develop on the lining of the stomach, small intestine, or esophagus due to excessive acid production or infection with Helicobacter pylori bacteria. By reducing stomach acid production, PPIs allow ulcers to heal and prevent their recurrence.
Gastritis: PPIs can help manage gastritis, inflammation of the stomach lining, by reducing the acidity of gastric juices and promoting healing of the inflamed tissue.
Zollinger-Ellison Syndrome: This rare condition is characterized by the overproduction of gastric acid, often due to tumors in the pancreas or duodenum. PPIs are used to control acid hypersecretion and alleviate associated symptoms such as abdominal pain and diarrhea.
Barrett's Esophagus: In patients with Barrett's esophagus, a condition where the cells lining the lower esophagus change due to chronic acid reflux, PPIs may be prescribed to reduce the risk of esophageal cancer by decreasing acid exposure to the esophageal mucosa.
Non-Ulcer Dyspepsia: PPIs are sometimes used to alleviate symptoms of non-ulcer dyspepsia, such as bloating, abdominal pain, and nausea, although their efficacy in this condition is less well-established compared to their use in GERD and peptic ulcers.
Gastric Acid Suppression: The primary mechanism of action of PPIs is the inhibition of gastric proton pumps (H+/K+-ATPase) in the stomach lining, leading to a reduction in the production of hydrochloric acid. This results in decreased acidity in the stomach, which can help alleviate symptoms associated with acid-related conditions.
Side Effects: While generally well-tolerated, proton pump inhibitors can cause side effects in some individuals. Common side effects may include headache, diarrhea, abdominal pain, nausea, constipation, and flatulence. Long-term use of PPIs has been associated with an increased risk of certain adverse effects, including bone fractures, vitamin B12 deficiency, magnesium deficiency, and an increased risk of certain infections such as Clostridium difficile colitis and pneumonia.
Drug Interactions: Proton pump inhibitors can interact with other medications, including anticoagulants, antiplatelet agents, benzodiazepines, and certain antibiotics, potentially affecting their metabolism and efficacy. It is important for healthcare providers to review a patient's medication list and consider potential interactions before prescribing PPIs.
Dependence: Long-term use of PPIs may lead to dependence on the medication for symptom control, and discontinuation can result in rebound acid hypersecretion, where acid production temporarily increases, potentially leading to symptoms such as heartburn.
Rank | Probiotic | Impact |
---|---|---|
genus | Arthrobacter | Increases |
genus | Bifidobacterium | Reduces |
genus | Pediococcus | Reduces |
order | Micrococcales | Increases |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium animalis | Reduces |
species | Bifidobacterium bifidum | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium catenulatum | Reduces |
species | Bifidobacterium longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
5 | 0 | Streptococcus | genus | Increases |
4 | 0 | Clostridioides difficile | species | Increases |
3 | 0 | Lactobacillus | genus | Increases |
3 | 0 | Campylobacter | genus | Increases |
2 | 1 | Lactobacillaceae | family | Increases |
2 | 1 | Turicibacter | genus | Decreases |
2 | 0 | Haemophilus | genus | Increases |
2 | 0 | Selenomonas | genus | Increases |
2 | 0 | Veillonella | genus | Increases |
2 | 0 | Actinomycetales | order | Increases |
2 | 0 | Helicobacter pylori | species | Decreases |
2 | 0 | Lacticaseibacillus rhamnosus | species | Increases |
1 | 4 | Streptococcaceae | family | Increases |
1 | 4 | Streptococcus sobrinus | species | Increases |
1 | 4 | Streptococcus iniae | species | Increases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive β X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 1.4 | -1.4 | |
Acne | 3.3 | 1.7 | 0.94 |
Addison's Disease (hypocortisolism) | 0.5 | -0.5 | |
ADHD | 5.5 | 7.4 | -0.35 |
Age-Related Macular Degeneration and Glaucoma | 1.3 | 0.2 | 5.5 |
Allergic Rhinitis (Hay Fever) | 6.2 | 6.5 | -0.05 |
Allergies | 8.4 | 12.3 | -0.46 |
Allergy to milk products | 5 | 5 | 0 |
Alopecia (Hair Loss) | 1.8 | 3.8 | -1.11 |
Alzheimer's disease | 17.4 | 12.8 | 0.36 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. β Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA β Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. β Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. β Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]